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A B S T R A C T
Purpose: Systematic evaluation of published evidence-base of the efﬁcacy of ﬁve antiepileptic drugs –
lacosamide, levetiracetam, valproate, phenytoin and phenobarbital – in convulsive benzodiazepine-
resistant status epilepticus.
Methods: Data sources included electronic databases, personal communication, and back tracing of
references in pertinent studies. These were prospective and retrospective human studies presenting
original data for participants with convulsive benzodiazepine-resistant status epilepticus. Interventions
were intravenous lacosamide, levetiracetam, phenobarbital, phenytoin and valproate. Outcome
measured is clinically detectable cessation of seizure activity. Level-of-evidence was assessed according
to Oxford Centre of Evidence-Based Medicine and The Cochrane Collaboration’s Tool for Assessment of
Risk. Twenty seven studies (798 cases of convulsive status epilepticus) were identiﬁed and 22 included
in a meta-analysis. Random-effects analysis of dichotomous outcome of a single group estimate
(proportion), with inverse variance weighting, was implemented. Several sources of clinical and
methodological heterogeneity were identiﬁed.
Results: Efﬁcacy of levetiracetam was 68.5% (95% CI: 56.2–78.7%), phenobarbital 73.6% (95% CI: 58.3–
84.8%), phenytoin 50.2% (95% CI: 34.2–66.1%) and valproate 75.7% (95% CI: 63.7–84.8%). Lacosamide
studies were excluded from the meta-analysis due to insufﬁcient data.
Conclusion: Valproate, levetiracetam and phenobarbital can all be used as ﬁrst line therapy in
benzodiazepine-resistant status epilepticus. The evidence does not support the ﬁrst-line use of
phenytoin. There is not enough evidence to support the routine use of lacosamide. Randomized
controlled trials are urgently needed.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Status epilepticus (SE) is a neurological emergency with
signiﬁcant morbidity and mortality1,2 and has to be treated in a
timely manner before irreversible neuronal damage ensues.3,4
Having a protocol for therapy is universally recommended, and
standard protocols are widely accepted.5,6 All of these recommend
benzodiazepines as ﬁrst line therapy7–17 and there is now global
consensus on this. In contrast, what action to take if benzodia-
zepines are ineffective is much less clear and there is perceived to
be a lack of evidence to support the use of any particular agent
currently employed in the protocols. Because of this paucity of
evidence, this review was conducted with the aim of examining,* Corresponding author at: Department of Internal Medicine, College of
Medicine/University of Babylon, Babil, Iraq. Tel.: +964 (0)7707117766.
E-mail address: z.yasiry@ucl.ac.uk (Z. Yasiry).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.12.007critically, the evidence relating to the efﬁcacy of ﬁve anti-epileptic
drugs in the treatment of benzodiazepine-resistant status epilep-
ticus. These medications are lacosamide, levetiracetam, valproate,
phenytoin and phenobarbital. The last two drugs have been
extensively used for this indication for many years, based largely
on the evidence derived from the Veterans Affair Trial8; although it
is worth noting that these medications were sometimes given as a
ﬁrst-line treatment in that study. The other three antiepileptic
drugs have been more recently introduced, and although widely
prescribed in this situation, are not licensed speciﬁcally for use in
status epilepticus.
2. Methods
2.1. Aims
To identify, via reproducible methodology, all the available
literature related to the use of the ﬁve anti-epileptic drugs invier Ltd. All rights reserved.
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geneity and reliability of the data, to analyze the extracted data to
quantify the relative efﬁcacy of these drugs, and to provide
recommendations for the use of the latter in patients with
benzodiazepine-resistant status epilepticus.
2.2. Patients, methods and analysis
A pre-speciﬁed protocol was followed for the search, extraction,
and analysis of data following the methodology of the ‘‘Systematic
Reviews: Centre of Review and Dissemination’s guidance for
undertaking reviews in health care’’ published by the Centre of
Review and Dissemination, University of York18 and ‘‘Cochrane
Handbook of Systematic Reviews of Intervention’’.19 Patients
reported in the published papers were included in the analysis
if they fulﬁlled the eligibility criteria set out in Table 1. All patients
with convulsive status epilepticus, of any type, and who had failed
to respond to benzodiazepine therapy and were thus given one of
the ﬁve study drugs as second-line therapy were included,
regardless of age or other clinical variable.
Internet-based searches were implemented through the online
databases MEDLINE and EMBASE, both accessed via Ovid (see
supplementary material 1 for search protocol). The search results
from the two databases were combined with the duplicates
excluded. In addition, the references in the bibliographies of the
relevant papers were individually searched and back-traced. In
several instances, the authors of the identiﬁed studies were
contacted via email or telephone, to answer speciﬁc queries
relating to data analysis in their papers (notably to ascertain details
of such aspects as the numbers of patients treated who were
benzodiazepine-resistant and their outcome).
The papers were selected for the review by screening the search
results by title and abstract for eligibility. The ﬁltered studies
would, then, be read as a whole, subjected to the inclusion criteria,
stratiﬁed according to the intervention of interest, and scrutinized
for their level of evidence and risk of bias. Then, they would goTable 1
Eligibility criteria.
Participants Patients with status epilepticus who have been resistant to
initial therapy with benzodiazepines were included. Only
human studies and studies of convulsive (motor) status
epilepticus were included. In some studies, simple and
complex partial seizures were not subdivided, and it is thus
possible that some non-convulsive cases were included;
however where a study exclusively included non-
convulsive status epilepticus, it was not considered. There
was no restriction by age groups, co-morbidities or epilepsy
background.
Interventions Intravenous lacosamide, levetiracetam, valproate,
phenytoin, and phenobarbital as second line therapy after
failure of benzodiazepines. No dose or rate restrictions were
speciﬁed.
Comparators None
Outcomes The variable extracted was cessation of seizure activity
(other outcomes were also sought but are not reported here
including, mortality, new neurological deﬁcit, and
tolerability). Cessation of seizure activity, or the drug’s
efﬁcacy, was deﬁned differently by different authors in the
selected papers, and deﬁnition was, therefore, reported as a
variable and acknowledged as one of the several sources of
heterogeneity.
Study design Original papers with any study design were included. There
was no restriction on the number of patients in case series.
All studies which provided data on outcome following
treatment with one (or more) of the ﬁve drugs were
included, whether these were controlled or uncontrolled
and whether or not a comparator was included.through data extraction, tabulation, pooling then meta-analysis, if
eligible for the latter.
Papers were excluded where original data was not presented
(for example reviews and expert opinions), which were published
in non-English languages without abstract/accredited translation
for the required data, where the drugs were used in more advanced
stages of status epilepticus (where benzodiazepines, then anaes-
thetics and other antiepileptic drugs had been used before the
medications of interest), and where data extraction/interpretation
was not possible.
The papers were classiﬁed into levels according to the Oxford
Centre of Evidence Based Medicine (CEBM).20 In case of random-
ized trials and non-randomized prospective studies, assessment of
the risk of bias was performed using the Cochrane Collaboration’s
Tool for Assessment of Risk.21
Data was extracted by ﬁlling out a proforma by one reviewer;
the process was supervised by the other reviewer. Data were then
analyzed using both STATA1 11 (by StataCorp LP, Texas, USA) and
Comprehensive MetaAnalysis version 2 (CMA21-by Biostat1, New
Jersey, USA). The protocol is based on dichotomous outcome
analysis of a single group estimate: inverse variance weighting is
performed for each estimate, followed by random-effects analysis
of the pooled estimates of all the studies describing an interven-
tion, taking in consideration both the within-study and between-
studies variances. The protocol and formulae for the random effect
meta-analysis are given in the supplementary material 2. Single-
patient case reports were not included in the meta-analysis due to
lack of statistical dispersion. There was one case of epilepsia
partialis continua found in the review, but as it was a single-patient
report, it was not included in the meta-analysis.
The reasons for choosing random-effects model are varying
sample sources, demographics, aetiology, and types of seizures,
treatment with different doses, timing of administration, and
deﬁnitions of outcome. All the aforementioned differences are
substantial sources of heterogeneity that make ﬁxed-effect meta-
analysis unsuitable. The random-effects model was not chosen
based on a statistical heterogeneity test.22 However, heterogeneity
was quantiﬁed via I2, a statistic used to quantify how much of the
variability in the results is due to real heterogeneity rather than a
random sampling error.23
3. Results
3.1. Characteristics of publications analyzed
A total of 2754 papers were identiﬁed on MEDLINE/EMBASE
(see supplementary material 1) from which 2652 papers were
excluded due to non-relevance. From the remaining 102 (with an
added 6 papers from reference tracing), only 27 papers were
retrieved for data extraction. Some studies covered two or three
drugs; therefore, the number of papers from summation of studies
per drug was 32. The papers included consist of 1 randomized
double-blinded trial, 5 open-label trials, 18 case series and 3 case
reports. They described 798 episodes of convulsive status
epilepticus.
The levels of evidence of the studies are as follows: level 4 (18
studies, 66%), level 4- (3 studies, 11%), level 2b (5 studies, 19%), and,
level 1b (1 study, 4%) (see supplementary material 3). For
prospective studies, assessment of the risk of bias was also
performed, the results of which are illustrated in Table 2. It is worth
noting that neither the prospective studies nor the single
randomized controlled trial are registered at the NIH Clinical Trial
Centre (http://clinicaltrials.gov/ct2/home).
Sources of heterogeneity were multiple; these include study
design (retrospective, prospective, randomized and non-random-
ized, blinded and non-blinded), demographics (age, gender,
Fig. 1. Forest plot for efﬁcacy of levetiracetam; CI: conﬁdence interval.
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istics (dosage, rate of infusion, manufacture, drug levels), and
condition characteristics (aetiology, semiology of seizures, dura-
tion of seizures to be considered status epilepticus, duration of
status before intervention), response characteristics (time to
seizure termination, presence of follow up period for re-emerging
seizures).
The deﬁnition of status epilepticus varied between studies: 10
papers (37%) used 5-min duration, while 5 other studies (18.51%)
speciﬁed the classical 30-min deﬁnition. Ten- and 20-min
durations of status were the criteria for 2 papers (3.7%, each);
while 15-min minimum was the criterion for 2 other studies
(7.4%). In 8 studies (29.6%), a deﬁnition for status epilepticus was
not speciﬁed. The deﬁnition of response to the intervention varied
as well. 14 papers (51.9%) speciﬁed a time-window in which
seizure termination was considered favourable. The most
common speciﬁcation was termination of seizures within
30 min of infusion (6 papers, 22.2%); other deﬁnitions include
3 min, 15 min, 20 min, 1 h, 12 h (1 paper for each, 3.7%), 24 h (2
papers, 7.4%) and 48 h (1 paper, 3.7%). A variable period of seizure
freedom was a secondary endpoint in 9 studies. The most common
time-window was 24 h (5 papers, 18.5%); other speciﬁed
windows include 6 h, 12 h, 48 h and 7 days (1 paper for each,
3.7%). No temporal deﬁnition of response was given in 12 papers
(44.4%). One study (3.7%) linked the time condition for seizure
freedom to the end of infusion.
Considering the above mentioned sources of heterogeneity, I2
was relatively low and within acceptable limits. The raw data from
the publications included in the analysis are available in the
supplementary material 4. Because of the heterogeneity or absence
of data on variables such as age, time of administration, prior
epilepsy, concurrent AEDs and AED levels, data was not stratiﬁed
according to these variables, although in any future study
(particularly in a randomized controlled trial) these would be
important variables to consider.Table 2
Assessment of the risk of bias in prospective studies.
Study name Selection bias: random
sequence generation
Selection bias:
allocation
concealment
Performanc
blinding (m
Agarwal et al. (2007) Unclear Unclear Unclear 
Chen et al. (2011) Low High High 
Kokwaro et al. (2003) High High High 
Misra et al. (2011) Low Unclear Unclear 
Ogutu et al. (2003) Unclear Unclear Unclear 
Malamiri et al. (2012) Low Low Low 3.2. Findings
3.2.1. Lacosamide
After applying the search methods, 109 papers were identiﬁed,
from which only 13 were retrieved, due to non-relevance of the
rest. From these 13, only 2 papers met the inclusion criteria. The
papers described treatment of a total of 70 patients with status
epilepticus of varying aetiologies, semiologies and stages.24,25 The
authors provided further data indicating which patients met our
inclusion criteria (i.e. second-line treatment after benzodiazepine
failure). Only 4 patients met these criteria, a number too small to
permit meta-analysis (see supplementary material 4 for details).
3.2.2. Levetiracetam
From original 345 papers identiﬁed from the search, 318 were
excluded by title/abstract screening. While 4 studies were added
via bibliography tracing, 21 studies were excluded after reviewing
the whole article. Thus, only 10 papers contributed to this review,
addressing the use of levetiracetam in 206 SE episodes.26–36 Two
reports were excluded from meta-analysis because each reported
only a single patient.28,31 The mean efﬁcacy from the remaining 8
studies was 68.5% (95% CI: 56.2–78.7%; Fig. 1). Heterogeneity
assessed by I2 was 12%. Averaged weighting of each contributing
study is available on the forest plot as percentage. Two papers,
those of Eue et al. (2011)26 and Alvarez et al. (2011)36, contribute
the most to these statistical results.
3.2.3. Phenobarbital
From 537 search results, 520 studies were excluded via the
title/abstract screening due to non-relevance. Seventeen papers
were retrieved of which 3 papers, reporting treatment of 43
episodes of benzodiazepine-resistant status epilepticus, were
considered eligible for inclusion.37–39 One case report was
excluded from the meta-analysis.39 The Meta-analysis revealed
a mean efﬁcacy of 73.6% (95% CI: 58.3–84.8%; Fig. 2). I2 was 0% duee bias:
asking)
Detection bias:
blinding of outcome
assessment
Attrition bias:
incomplete outcome
data
Reporting bias:
selective outcome
reporting
Low Unclear High
Low Low Low
High Low Low
Low Unclear Unclear
Low Low Low
Low Low Low
Fig. 2. Forest plot for efﬁcacy of phenobarbital; CI: conﬁdence interval.
Fig. 3. Forest plot for efﬁcacy of phenytoin; CI: conﬁdence interval.
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supplementary material 2 for complete reference of the random-
effects model). Averaged weighting of each contributing study is
available on the forest plot as percentage, with Malamiri et al.
(2012)38 contributing to more than two thirds of the statistical
weight.
3.2.4. Phenytoin
There were 996 papers as the result of the protocol used for
databases search. 968 papers were excluded via title/abstract
screening. The remaining 28 papers were retrieved for further
inspection. Only 8 studies, reporting 294 episodes of status
epilepticus, meet the inclusion criteria.36,40–46Meta-analysis of the
pooled effect sizes showed a mean efﬁcacy of 50.2% (95% CI: 43.2–
66.1%; Fig. 3). Heterogeneity via I2 was calculated to be 16.45%.
Averaged weighting of each contributing study is available on the
forest plot. Alvarez et al. (2011)36 and Brevoord et al. (2005)43 seem
to contribute the most to the statistical results.
3.2.5. Valproate
After applying the search protocol, 767 results were identiﬁed.
Seven hundred forty two papers were excluded due to non-
relevance by title/abstract screening; 2 were added via reference
tracing to give a net total of 27 papers. These were assessed, andFig. 4. Forest plot for efﬁcacy of valﬁnally 9 papers, describing treatment in 251 benzodiazepine-
resistant episodes, were included.36,38,45–51 One case report was
excluded from the meta-analysis51 while the remaining 8 studies
yielded a mean effect size for the efﬁcacy of valproate of 75.7% (95%
CI: 63.7–84.8%; Fig. 4). Heterogeneity calculated via I2 was 12.73%.
Averaged weighting of each contributing study is available on the
forest plot as percentage. Alvarez et al. (2011)36 and Chen et al.
(2011)50 seem to contribute the most to the statistical results.
4. Discussion
4.1. Limitations
To the best of our knowledge, this is the ﬁrst attempt, to review
the ﬁve antiepileptic drugs for use in patients with status
epilepticus who have failed to respond to initial benzodiazepine
treatment (as recommended by most of the current protocols), and
to implement a meta-analysis of the ﬁndings.
The strength of the study is its strictly applied inclusion criteria,
and the systematic search, method and analysis. However, the
investigation revealed a number of important limitations:
a. The number of studies that have addressed the effectiveness of
second-line therapy is small (27 papers).proate; CI: conﬁdence interval.
Z. Yasiry, S.D. Shorvon / Seizure 23 (2014) 167–174 171b. The studies are mostly observational and retrospective (21;
77.7%).
c. There is near-total absence of randomized double-blinded trials
(Class I evidence) to compare the interventions (1; 3.7%).
d. For the few prospective studies, most are open-label (5; 18.5%),
with high risk of bias in multiple domains.
e. There is also a lack of homogeneity in the ﬁndings – few studies
sharing comparable questions, outlines of methodology, aims,
or even deﬁnitions of variables (such as status epilepticus) and
main endpoints (such as the response or its duration). This has
caused signiﬁcant clinical and statistical heterogeneity, and
limited an original intention to study the inﬂuence of variables
in correlation analysis. In addition, this heterogeneity compro-
mises the strength of evidence derived from this review, as the
confounders cannot be taken, statistically, into account.
f. The random-effects model adopted for the meta-analysis has
resulted in estimates with wide conﬁdence intervals (i.e. larger
uncertainty) and, therefore, less powerful impact.
g. In some settings, current practice is to use second-line
treatment immediately or very soon after a full dose of
benzodiazepine, especially diazepam, to avoid the potential of
recurrence of seizures. Neither this practice nor the adequacy of
ﬁrst line treatment was appropriately assessed in the partici-
pating studies.
These limitations are important. Any decisions about drug
therapy need to be made in the knowledge that the published
literature is not wholly adequate and that the evidence base on
which to make comparisons of studies of different designs, with
different deﬁnitions and which do not consider other variables is
poor. Such a situation though is not uncommon in other clinical
settings, particularly in relation to emergency therapy. Certainly,
better quality studies are needed before gold-standard recom-
mendations can be made. One main outcome of our analysis is to
highlight these weaknesses. Nevertheless, advice regarding
therapy is needed, even in the absence of optimal data.
4.2. Choice of drugs
Here we present our ﬁndings from the meta-analysis and
narrative ﬁndings regarding side-effects from the published
literature for each drug. In making comparisons, in the absence
of any randomized controlled trial (RCT) in which direct
comparisons are reported, our conclusions must be inevitably to
an extent subjective. Furthermore, as emphasized in the sections
on limitations, there are other important clinical factors which
inﬂuence outcome in status epilepticus. Our recommendations are
therefore provisional and indirectly based, but made on what we
consider the best available evidence. We have focused on adult SE
and there are suggestions for some drugs that efﬁcacy in paediatric
populations may differ. Cost-beneﬁt assessments would also be
useful, but cannot be made as controlled data related to
comparison of side-effects and complication rates, and other
economic variables are not systematically reported. One particular
issue of interest would be whether treatment, especially in
refractory cases, may sometimes worsen outcome. This requires
separate and speciﬁc study.
4.2.1. Lacosamide
There is not enough evidence to recommend using lacosamide
routinely in the treatment of benzodiazepine-resistant status
epilepticus at present, despite the accumulating studies com-
mending on its efﬁcacy in individual cases. Nevertheless, the drug
has favourable properties including a possible novel mode of
action and an absence of signiﬁcant side-effects and interactions,
which might favour its use in the future especially for patients withco-morbidities and those on polytherapy.52 From these studies, it
is clear that Lacosamide can be effective and safe, in a 200–400 mg
bolus dose range in adult patients; however, the magnitude of this
efﬁcacy cannot, yet, be compared to the other medications. Data on
its usage and dosing in paediatric SE is lacking.
4.2.2. Levetiracetam
The estimated mean efﬁcacy of levetiracetam is 68.5%, when
infused in doses between 1000 and 3000 mg in young adults, or
20 mg/kg. Experience is relatively limited, but suggests to date that
the drug is free of signiﬁcant adverse-effect and well tolerated in
paediatric, adult and elderly populations and in those with
comorbidities. It has neither common cardio-respiratory side-
effects nor drug–drug interactions.53
4.2.3. Phenobarbital
Phenobarbital has an estimated efﬁcacy, in the meta-analysis,
of 73.6%; however, the conﬁdence interval was very wide (95% CI:
58.3–84.8%), making the clinical relevance of this result unclear.
This efﬁcacy, when supported by a potential neuroprotective
effect, is a signiﬁcant advantage. Disadvantages include adverse
effects that limit its use, such as respiratory depression, hypoten-
sion, severe sedation, tolerance and the potential for drug
interactions.6,54
4.2.4. Phenytoin
Phenytoin had a mean efﬁcacy estimate of 50.2%. In the
reported studies, phenytoin was administered in doses classically
recommended to produce a therapeutic blood level, but it is well-
established that drug level monitoring is needed in view of the
non-linear kinetics of phenytoin.55–57 This was, often, not reported
(87.5% of studies did not report the levels), and one possible reason
for relatively low efﬁcacy reported in some patients may have been
inadequate levels. Another possible explanation is the fact that
lower cerebral concentrations of phenytoin in animal models are
found in lesional brain foci of seizure activity.58–61 Other
disadvantages are the absence of data substantiating its use for
older population (due to expected high rate of cardiovascular
adverse-events) and for neuroprotection, where it may also be
detrimental in certain types of brain injury.62 Advantages, though,
are its long duration of action, fast CNS entry,63–65 availability and
large experience accrued over decades of use. The side-effects of IV
phenytoin include signiﬁcant cardio-respiratory risks (cardiac
arrhythmia, hypotension, reduced cardiac output)66,67 and also
risks of thrombosis and inﬂammation at the injection site
sometimes resulting in distal ischaemia (the ‘purple-glove’
syndrome).68–71 In view of the above points, although phenytoin
is often considered the drug of ﬁrst choice in benzodiazepine-
resistant status, the published evidence does not appear to support
this practice.
4.2.5. Valproate
The meta-analysis found the mean efﬁcacy of valproate to be
75.7%. The fact all the comparative, prospective and randomized
studies include valproate as one of their two or three arms gives
more power to the statistical analysis. In addition to its high
efﬁcacy in acute situation, follow-up seizure freedom rates were
also higher, and the drug was well-tolerated, even with large doses
(up to 100 mg/kg) and rates of infusion (up to 6 mg/kg/min). It
is free of cardio-respiratory side effects which is an important
advantage. However, high doses of IV valproate are likely to cause
hyperammonaemia and in susceptible patients, it is likely that
ammonia concentrations could rise to very high and potentially
dangerous levels although data on this is lacking.72,73 There is a risk
of hepatic and pancreatic toxicity, and valproate encephalopa-
thy.73 There is also a theoretical risk that the use of high dose
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platelets and platelet function74, which might carry risks in some
situations in status epilepticus (for instance in acute stroke), but to
the best of our knowledge no such side-effects have been reported
in practice in status epilepticus.
4.3. Other factors inﬂuencing outcome
Several signiﬁcant factors may inﬂuence the chance of seizure
cessation and ﬁnal outcome(s) of status epilepticus. These have
been outlined as sources of heterogeneity above, and include
variables such as the adequacy of ﬁrst line therapy, the duration of
status epilepticus before treatment was initiated, the aetiology of
seizures, the age of the patients, and dosage and rate of infusion of
the drug. This meta-analysis could not analyze these variables or
use them to interpret the outcome differences because of missing
data.
Several other observations were made about outcome from this
analysis of the literature. First, there seems wide agreement that
the duration of seizures before treatment was inversely related to
the probability of clinical seizure cessation, whatever treatment is
chosen, i.e. the longer the seizures prior to treatment, the less likely
they are controlled by medications.40,42,43,46,48,50 Second, aetiology
is a most important variable to account for both treatment failure
and adverse long-term outcome, with symptomatic seizures
carrying the poorest response to second-line treatment.30,36,43,50
Finally, there are a variety of ﬁndings about whether seizure type
inﬂuences outcome in the various studies of drug effect, and no
agreement on this point.26,33,36,48 These data require further
research via prospective designs of future studies in which
multiple variables are controlled to explore the effects of
individual factors on primary and secondary treatment outcomes.
4.4. Recommendations for treatment
Although there are few controlled studies and a general poverty
of data, we consider that the data reviewed above provide
sufﬁcient evidence for limited recommendations to be made.
The highest efﬁcacy was attributed to valproate, levetiracetam and
phenobarbital. Each of these drugs has differing advantages and
drawbacks. Taken altogether, it is our view that any of these three
could have claim to be ﬁrst line therapy in benzodiazepine-
resistant status epilepticus in most patients. There are differing
clinical situations where one might be preferred over the others –
for instance the avoidance of phenobarbital where the risk of
hypotension or respiratory depression are signiﬁcant or the
avoidance of valproate where there is a particular susceptibility
to hyperammonaemia or hepatic failure (possibly in children with
mental handicap). We consider that the many disadvantages of IV
phenytoin, linked to its lower efﬁcacy, make this an unattractive
choice for ﬁrst-line therapy in benzodiazepine-resistant cases
despite its wide usage in this situation globally. Lacosamide is a
much newer compound with theoretical advantages, but the
published experience is so slight that more studies are required, in
our view, before it can be recommended as either a ﬁrst or second-
line antiepileptic drug in benzodiazepine-resistant status epilep-
ticus.
From this literature review, the following dosages in adults
seem most commonly or effectively employed: valproate – 20–
30 mg/kg as a bolus dose with a maximal infusion rate of 6 mg/kg/
min; levetiracetam – bolus dose of 20 mg/kg or 1000–2000 mg in a
rate of 1–1.5 mg/kg/min or 100 mg/min; phenobarbital 20 mg/kg
at a rate of 50–75 mg/min; phenytoin 15–20 mg/kg in a rate of
50 mg/min; lacosamide 400 mg with an infusion rate of 40–80 mg/
min. These doses apply to adults without systemic complications
such as hepatic, renal or mitochondrial disease (the latter being aparticular contra-indication to the use of valproate) or those with
other conditions or comorbidities which might interfere with their
prescription.
These recommendations are made, we fully recognize, on an
evidence base which is small and inadequate. Comparison with
existing guidelines and reviews could be made, but these too are
based generally on an inadequate controlled data base. More
deﬁnitive recommendations can only be made on the basis of well-
conducted randomized trial data, preferably with each medication
compared to another. From the participating studies, only the
paper of Malamiri et al.38 fulﬁlled all the criteria of a successful
randomized double-blinded trial in status epilepticus therapeutics.
There is a proposed study – the Established Status Epilepticus
Treatment Trial (ESETT)75 – currently in the planning stage, and it
is hoped that this study will greatly improve the evidence on which
to base recommendations.
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